These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25329072)

  • 1. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China.
    Qiu Q; Li Y; Duan XW; Yang LK; Chen Y; Li H; Wang L; Duan ZP
    PLoS One; 2014; 9(10):e109652. PubMed ID: 25329072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence.
    Qiu Q; Duan XW; Li Y; Yang LK; Chen Y; Li H; Duan ZP; Wang L
    World J Gastroenterol; 2015 Aug; 21(32):9588-97. PubMed ID: 26327766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.
    Li M; Kong YY; Wu SS; Zhou JL; Wu XN; Wang L; Su JT; Ou XJ; You H; Xie XQ; Wei ZH; Jia JD
    J Dig Dis; 2019 Sep; 20(9):467-475. PubMed ID: 31231938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral drug utilization and annual expenditures for patients with chronic HBV infection in Guangzhou, China, in 2008-2015.
    Zhou F; Jia W; Yang S; Chen G; Li G; Li Y; Liang Y; Yang Y; Gao Y; Chen Y
    Antivir Ther; 2019; 24(6):405-416. PubMed ID: 31348006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
    Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
    Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
    J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursement policies in the Asia-Pacific for chronic hepatitis B.
    Lim SG; Amarapurkar DN; Chan HL; Crawford DH; Gane EJ; Han KH; Ahn SH; Jafri W; Jia J; Kao JH; Lesmana LA; Lesmana CR; Mohamed R; Phiet PH; Piratvisuth T; Sarin SK; Sollarno JD; Eguchi Y; Mahtab MA; Lee KH
    Hepatol Int; 2015 Jan; 9(1):43-51. PubMed ID: 25788378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
    Arama V; Leblebicioglu H; Simon K; Zarski JP; Niederau C; Habersetzer F; Vermehren J; Bludzin W; Jinga M; Ulusoy S; Klauck I; Morais E; Bjork S; Lescrauwaet B; Kamar D; Zeuzem S;
    Antivir Ther; 2014; 19(3):245-57. PubMed ID: 24343051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of treating chronic hepatitis B: comparison of current treatment guidelines.
    Robotin M; Patton Y; Kansil M; Penman A; George J
    World J Gastroenterol; 2012 Nov; 18(42):6106-13. PubMed ID: 23155339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
    Yuan Y; Iloeje U; Li H; Hay J; Yao GB
    Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China.
    Yong M; Xianjun X; Jinghu L; Yunyun F
    Aust Health Rev; 2018 Feb; 42(1):39-44. PubMed ID: 28263706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study.
    Yang S; Chen G; Li Y; Li G; Liang Y; Zhou F; Zhou S; Yang Y; Jia W; Gao Y; Chen Y
    BMC Med Inform Decis Mak; 2021 Jul; 21(Suppl 2):71. PubMed ID: 34330262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral therapy for chronic hepatitis B in China.
    Zheng X; Wang J; Yang D
    Med Microbiol Immunol; 2015 Feb; 204(1):115-20. PubMed ID: 25540038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China.
    Hu M; Chen W
    Value Health; 2009; 12 Suppl 3():S89-92. PubMed ID: 20586991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
    Juday T; Tang H; Harris M; Powers AZ; Kim E; Hanna GJ
    J Gen Intern Med; 2011 Mar; 26(3):239-44. PubMed ID: 20978862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
    Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
    Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.